Security key
H5870P110
- Security type / class
- Equity / *W EXP 03/06/202
- Total 13F shares
- 252,371
- Total 13F value
- $2,183,517
- Share change
- -9,625
- SEC-reported price per share
- $8.56
- Number of holders
- 10
- Value change
- -$82,539
- Number of buys
- 2
- Number of sells
- 3
Report period
Q4 2025
Institutions
10
Top holders
10
OCSAW full security history
Ownership snapshot
Full 13F holder table
Oculis Holding AG SEC filings
Oculis Holding AG company facts
Broader feeds
Ownership snapshot
Top reported holders of OCSAW - Oculis Holding AG - *W EXP 03/06/202 (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Pivotal bioVenture Partne...
Disclosed value leader
EQT Fund Management S.a r.l.
Comparable rows
15/15
Latest evidence
30 Sep 2025
13D/G
13F
Lead comparable stake: 4.9%
13D/G row: Pivotal bioVenture Partners Fund I, L.P.
Showing 1-6 of 15 holder rows.
Quick read
Pivotal bioVenture Partners Fund I, L.P. leads the comparable SEC ownership view at 4.9%.
15 of 15 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Pivotal bioVenture Partners Fund I, L.P.'s linked filing trail.
Comparable ownership
Top 5
Pivotal bioVenture Partners Fund ...
4.9%
EQT Fund Management S.a r.l.
10%
Pivotal bioVenture Partners Inves...
3.9%
Aberdeen Group plc
2.1%
Nan Fung Group Holdings Ltd
0.87%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-6 of 15 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Pivotal bioVenture Partners Fund I, L.P. |
13D/G
Nan Fung Group Holdings Limited
|
4.9%
|
$49,946,544
2,815,476 shares
|
$0 | 30 Sep 2025 |
| EQT Fund Management S.a r.l. |
13F
Company
|
10%
|
$103,727,169
5,900,294 shares
|
— | 30 Sep 2025 |
| Pivotal bioVenture Partners Investment Advisor LLC |
13F
Company
|
3.9%
|
$40,447,607
2,300,774 shares
|
— | 30 Sep 2025 |
| Aberdeen Group plc |
13F
Company
|
2.1%
|
$22,217,800
1,253,119 shares
|
— | 30 Sep 2025 |
| Nan Fung Group Holdings Ltd |
13F
Company
|
0.87%
|
$9,048,461
514,702 shares
|
— | 30 Sep 2025 |
| SR ONE CAPITAL MANAGEMENT, LP |
13F
Company
|
0.55%
|
$5,669,550
322,500 shares
|
— | 30 Sep 2025 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
13F holder rows
Institutional holders as of Q4 2025
Investor-level positions for this CUSIP, loaded as an interactive table.
Institutions
10
Shares
252,371
Rows available
10
| Investor | Option | Weight % | Change % | SEC-reported value | * Price | Shares | Share Change | Activity | Report Period |
|---|
* SEC-reported price is the security price as of the portfolio date and can indicate the last known price at which the security was still held. The marker flags a reported price that did not pass the local price check.
Compare Q4 2025 vs Q3 2025 Across Filers
Q3 2025 holders
10
Q4 2025 holders
10
Holder diff
0
| Investor | Q3 2025 Shares | Q4 2025 Shares | Share Diff | Share Chg % | Q3 2025 value | Q4 2025 value | Value change | Value Chg % |
|---|